Anti-influenza A virus effect of Hypericum perforatum L. extract

Virologica Sinica

Volumn 24, Issue 1, 2009, Pages 19-27

  Pu, Xiu ying ^a,b   Liang, Jian ping ^b,c   Wang, Xue hong ^b   Xu, Tao ^a   Hua, Lan ying ^b   Shang, Ruo feng ^b   Liu, Yu ^b   Xing, Yan mei ^a  

^a GANSU AGRICULTURAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

^c INSTITUTE OF MODERN PHYSICS   (China)

Author keywords

Hypericumperforatum L. extract (HPE); Influenza A virus (IAV); Ribavirin

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; RIBAVIRIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTERIAL OXYGEN SATURATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; INFLUENZA; INFLUENZA VIRUS A; LD 50; MORTALITY; MOUSE; NONHUMAN; THERAPY DELAY; TREATMENT DURATION;

HYPERICUM PERFORATUM; INFLUENZA A VIRUS; MUS;

EID: 61349105356     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-009-2983-x     Document Type: Article

References (40)

1. Andersen D O, Weber N D, Wood, S G, et al. 1991. In vitro virucidal activity of selected anthraquinones and anthraquinones derivatives. Antiviral Res, 16(2): 185-196.
2. Barnard D L, Huffman J H, Morris J L, et al. 1992. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinones derivatives against human cytomegalovirus. Antiviral Res, 17:63-77.
3. Baytop T. 1984. Therapy with Herbs in Turkey. Istanbul: Istanbul Univ. Press, p185-186.
4. Bone K. 1994. The herbal treatment of viral infections. Eur J Herbal Med, 1: 23-28.
5. Che C T. 1991. Plants as a source of potential antiviral agents, Econ. Med Plant Res, 5: 167-251.
6. Hayden F G, Belshe R B, Villaneueva C, et al. 2004. Management of influenza in households: A prospective randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. J Infect Dis, 189: 440-449.
7. Herekman-Demir T, Öztürk N, Öztürk Y, 2001. Hepatoprotective effect of St. John's Wort. Fund Clin Pharmacol, 15: 104.
8. Hillyard I W. 1980. The preclinical toxicology and safety of ribavirin. In: Ribavirin: A Broad-Spectrum Antiviral Agent (Smith R A, Kirkpatrick W. eds.). New York: Academic Press, p59-71.
9. Hobbs C. 1989. St John's Wort. Hypericum perforatum L: A review. Herbal Gram, 18:24-33.
10. Hudson J B, Lopez-Bazzocchi I, Towers G H. 1991. Antiviral activities of hypericin. Antiviral Res, 15(2): 101-112.
11. Hudson J B. 1992. Antiviral Compounds from Plants. Florida: CRC Press, p162.
12. Huffman J H, Sidwell R W, Khare G P, et al. 1973. In vitro effect of 1-β-d-ribofuranosy-1, 2, 4-triazole-3-carboxamide (Virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother, 3: 235-241.
13. Khare G P, Sidwell R W, Witkowski J T, et al. 1973. Suppression by 1-β-d-ribofuranosyl -1, 2, 4-triazole-3-carboxamide (Virazole, ICN 1229) of influenza virusinduced infections in mice. Antimicrob Agents Chemother, 3: 235-238.
14. Lavie G, Mazur Y, Lavie D, et al. 1995. The chemical and biological properties of hypericin compound with broad spectrum of biological activity. Med Res Rev, 15(2): 111-119.
15. Lavie G, Valentine F, and Levin B, et al. 1989. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA, 86:5963-5967.
16. Lenard J, Rabson A, Vanderoef R. 1993. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation. Proc Natl Acad Sci USA, 90: 158-162.
17. Li H, Jiang H C. 2007. Antibacterial effect of the total extract of Hypericum perforatum on clinically isolated bacteria. Guihaia, 27(3): 466-468. (in Chinese)
18. Li K S, Guan Y, Wang J, et al. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature, 430: 209-213.
19. Liu X J, Li Y L, Xi F Z. 2003.The therapeutic function and effection on VEGF, Flt- 1 and MVD about photo-activated hypericin to rat C6 glioma. Chin J Lab Diag, 7(6): 524-526. (in Chinese)
20. Nicholson K G, Wood J M, Zambon M. 2003.Influenza. Lancet, 362(9397): 1733-1745.
21. Nicolaeva V T. 1977. Plants used by some nations in the USSR for diseases of the liver and biliary ducts. Rastitel'nye Resursy, 13:396-403.
22. Öztürk Y, Aydin S, Beis R, et al. 1996. Effects of Hypericum calycinum L. extract on the central nervous system in mice. Phytotherapy Research, 10: 700-702.
23. Öztürk Y, Aydin S, Beis R, et al. 1996. Effects of Hypericum perforatum L. and Hypericum calycinum L. extracts on the central nervous system in mice. Phytomedicine, 3: 137-144.
24. Öztürk Y. 1997. Testing antidepressant effects of Hypericum species on animal models. Pharmacopsy-chiatry, 30: 125-128.
25. Öztürk Y, Aydin S, Baser K H C, et al. 1992. Hepatoprotective activity of Hypericum perforatum L. alcoholic extract in rodent. Phytotherapy Research, 6: 44-46.
26. Patriarca P A, Weber J A, Parker R A, et al. 1985. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA, 253(8): 1136-1139.
27. Sandstrom E. 1989. Antiviral therapy in human immunodeficiency virus infection. Drugs, 38:417-450.
28. Schinazi R F, Chu C K, Babu J R, et al. 1990. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res, 13(5): 265-272.
29. Serkedjieva J, Manolova N, Zgorniak-Nowosielska I, et al. 1990. Antiviral activity of the infusion (SHS-174) from flowers of sambucus nigra L., aerial parts of Hypericum perforatum L., and roots of Saponaria officinalis L. against influenza and herpes simplex viruses. Phytother Res, 4:97-100.
30. Sidwell R W, Huffman J H, Khare G P, et al. 1972. Broad-spectrum antiviral activity of virazole: 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science, 177:705-706.
31. Sidwell, R W. 1996. Ribavirin: A review of antiviral efficacy. in: Recent Res Devel, Antimicrob Agents CH (Pandalai G. ed), vol. 1, Kerala, India, Research Signpost, p219-256.
32. Sidwell R W, Huffman J H, Gilbert J, et al. 1992. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob Agents Chemother, 36:473-476.
33. Sidwell R W, Huffman J H, Barnard D L, et al. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res, 37:107-120.
34. Sidwell R W, Smee D F, Huffman J H, et al. 2001b. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res, 51:179-187.
35. Smee D F, Huffman J H, Morrison A C, et al. 2000. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother, 45:743-748.
36. Tang J, Colacino J M, Larsen S H, et al. 1990. Virucidal activity of hypericin against enveloped and non enveloped DNA and RNA viruses. Antiviral Res, 13(6): 313-325.
37. Thiers B H. 1989. Antiretroviral therapy. J Am Acad Dermatol, 21/3 I: 443-454.
38. Jefferson T, Demisheli V. 1998. Socioeconomics of influenza. In: Textbook of Influenza (Nicholson K G, Webster R G, Hay A J. eds.), Oxford, UK: Blackwell Sciences, p541-547.
39. Vanden Berghe D A, Vlietinck A J, Van Hoof L. 1986. Plant products as potential antiviral agents, Bull Inst Pasteur, 84:101-147.
40. Pei-Gen X. 1994. Ethnopharmacological investigation of Chinese medicinal plants. In: Prance, G T, Derek J, March J. (Eds.), Ethnobotany and the Search for New Drugs, Ciba Foundation Symposium, vol. 185. John Wiley and Sons, Chichester, p169-177.